Navigation Links
DURECT Corporation to Participate in Upcoming Healthcare Conferences

CUPERTINO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY.


-- Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4th at 3:20 p.m. Eastern Time.

-- Barclays Capital Small & Mid-Cap Healthcare Forum on Thursday, November 6th at 2:30 p.m. Eastern Time.

-- Rodman & Renshaw Annual Global Healthcare Conference on Tuesday, November 11th 5:20 p.m. EST.

A live audio webcast of the presentations will be available by accessing DURECT's homepage at and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM) and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit

NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM) and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call
2. DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
3. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
4. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
5. DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
6. DURECT to Participate in Morgan Stanley Global Healthcare Conference
7. DURECT Provides Update on CHRONOGESIC(R) Research Program
8. DURECT to Participate in Cowen Annual Healthcare Conference
9. DURECT to Participate in Susquehanna Financial Healthcare Conference
10. DURECT to Present at BIO CEO Investor Conference 2008
11. DURECT to Present at 2007 BIO Investor Forum
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has issued ... from extreme heat at their worksites. Employers with workers exposed to high ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: